Spyre Therapeutics IncNASDAQ:SYRE
- LAST PRICE27.5950
- TODAY'S CHANGE (%)-0.1050 (-0.3791%)
- Bid / Lots27.5700/ 6
- Ask / Lots27.6700/ 1
- Open / Previous Close28.2600 / 27.7000
- Day Range
- 52 Week Range
- Volume319,955
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SYRE |
|---|---|---|
| 09:32 ET | 3294 | 27.935 |
| 09:33 ET | 300 | 27.495 |
| 09:35 ET | 400 | 27.99 |
| 09:37 ET | 2140 | 27.975 |
| 09:39 ET | 400 | 28.16 |
| 09:42 ET | 500 | 28.0775 |
| 09:44 ET | 8242 | 28 |
| 09:46 ET | 500 | 28.05 |
| 09:48 ET | 630 | 27.92 |
| 09:51 ET | 700 | 27.715 |
| 09:53 ET | 300 | 27.63 |
| 09:55 ET | 200 | 27.61 |
| 09:57 ET | 600 | 27.62 |
| 10:00 ET | 400 | 27.615 |
| 10:02 ET | 1300 | 27.57 |
| 10:04 ET | 2300 | 27.555 |
| 10:06 ET | 700 | 27.66 |
| 10:08 ET | 1400 | 27.715 |
| 10:09 ET | 600 | 27.84 |
| 10:11 ET | 400 | 27.735 |
| 10:13 ET | 1100 | 27.665 |
| 10:15 ET | 1075 | 27.68 |
| 10:18 ET | 300 | 27.8 |
| 10:20 ET | 800 | 27.73 |
| 10:22 ET | 500 | 27.725 |
| 10:24 ET | 700 | 27.72 |
| 10:27 ET | 300 | 27.76 |
| 10:29 ET | 500 | 27.755 |
| 10:31 ET | 2465 | 27.74 |
| 10:33 ET | 500 | 27.59 |
| 10:36 ET | 1600 | 27.64 |
| 10:38 ET | 1223 | 27.655 |
| 10:40 ET | 500 | 27.74 |
| 10:42 ET | 200 | 27.715 |
| 10:44 ET | 400 | 27.68 |
| 10:45 ET | 1346 | 27.83 |
| 10:47 ET | 11727 | 28.025 |
| 10:49 ET | 400 | 27.965 |
| 10:51 ET | 2900 | 27.96 |
| 10:54 ET | 10325 | 28.12 |
| 10:56 ET | 1300 | 28.115 |
| 10:58 ET | 4822 | 28.12 |
| 11:00 ET | 881 | 28.035 |
| 11:02 ET | 611 | 28 |
| 11:03 ET | 400 | 27.98 |
| 11:05 ET | 435 | 28.05 |
| 11:07 ET | 325 | 28.05 |
| 11:09 ET | 600 | 28.025 |
| 11:12 ET | 1700 | 28.015 |
| 11:14 ET | 4920 | 28.03 |
| 11:16 ET | 713 | 28.08 |
| 11:18 ET | 5540 | 27.89 |
| 11:20 ET | 200 | 27.87 |
| 11:21 ET | 470 | 27.905 |
| 11:23 ET | 300 | 27.905 |
| 11:25 ET | 500 | 27.915 |
| 11:27 ET | 200 | 27.91 |
| 11:30 ET | 1000 | 27.79 |
| 11:32 ET | 600 | 27.86 |
| 11:34 ET | 300 | 27.85 |
| 11:36 ET | 400 | 27.82 |
| 11:38 ET | 2422 | 27.595 |
| 11:39 ET | 500 | 27.59 |
| 11:41 ET | 200 | 27.59 |
| 11:43 ET | 330 | 27.6 |
| 11:45 ET | 500 | 27.5675 |
| 11:48 ET | 900 | 27.66 |
| 11:50 ET | 5620 | 27.57 |
| 11:52 ET | 1251 | 27.46 |
| 11:54 ET | 1424 | 27.55 |
| 11:56 ET | 429 | 27.6 |
| 11:57 ET | 200 | 27.57 |
| 11:59 ET | 300 | 27.58 |
| 12:01 ET | 800 | 27.54 |
| 12:03 ET | 200 | 27.545 |
| 12:06 ET | 1500 | 27.51 |
| 12:08 ET | 200 | 27.505 |
| 12:10 ET | 1460 | 27.5 |
| 12:12 ET | 3400 | 27.51 |
| 12:14 ET | 1800 | 27.46 |
| 12:15 ET | 1200 | 27.35 |
| 12:17 ET | 3840 | 27.535 |
| 12:19 ET | 1088 | 27.54 |
| 12:21 ET | 788 | 27.55 |
| 12:24 ET | 6791 | 27.52 |
| 12:26 ET | 1636 | 27.5 |
| 12:28 ET | 200 | 27.52 |
| 12:30 ET | 3388 | 27.31 |
| 12:32 ET | 800 | 27.235 |
| 12:33 ET | 900 | 27.32 |
| 12:35 ET | 200 | 27.37 |
| 12:37 ET | 1900 | 27.37 |
| 12:39 ET | 300 | 27.44 |
| 12:42 ET | 459 | 27.45 |
| 12:44 ET | 615 | 27.45 |
| 12:46 ET | 200 | 27.44 |
| 12:48 ET | 900 | 27.365 |
| 12:50 ET | 1300 | 27.41 |
| 12:51 ET | 427 | 27.435 |
| 12:53 ET | 600 | 27.48 |
| 12:55 ET | 200 | 27.48 |
| 12:57 ET | 1300 | 27.51 |
| 01:00 ET | 1899 | 27.53 |
| 01:02 ET | 1191 | 27.72 |
| 01:06 ET | 200 | 27.69 |
| 01:08 ET | 200 | 27.65 |
| 01:09 ET | 100 | 27.6 |
| 01:11 ET | 100 | 27.615 |
| 01:13 ET | 600 | 27.595 |
| 01:15 ET | 300 | 27.62 |
| 01:18 ET | 1200 | 27.52 |
| 01:20 ET | 220 | 27.48 |
| 01:22 ET | 100 | 27.44 |
| 01:24 ET | 737 | 27.45 |
| 01:26 ET | 930 | 27.44 |
| 01:27 ET | 200 | 27.425 |
| 01:29 ET | 100 | 27.4 |
| 01:31 ET | 300 | 27.36 |
| 01:33 ET | 300 | 27.405 |
| 01:36 ET | 600 | 27.41 |
| 01:38 ET | 1800 | 27.475 |
| 01:40 ET | 700 | 27.46 |
| 01:42 ET | 537 | 27.41 |
| 01:44 ET | 700 | 27.425 |
| 01:45 ET | 100 | 27.425 |
| 01:47 ET | 1300 | 27.48 |
| 01:49 ET | 900 | 27.51 |
| 01:51 ET | 1500 | 27.5 |
| 01:54 ET | 1600 | 27.47 |
| 01:56 ET | 700 | 27.47 |
| 01:58 ET | 5159 | 27.47 |
| 02:00 ET | 1700 | 27.51 |
| 02:02 ET | 1100 | 27.61 |
| 02:03 ET | 2400 | 27.67 |
| 02:05 ET | 1001 | 27.64 |
| 02:07 ET | 3375 | 27.675 |
| 02:09 ET | 1200 | 27.81 |
| 02:12 ET | 2900 | 27.81 |
| 02:14 ET | 1100 | 27.81 |
| 02:16 ET | 1200 | 27.78 |
| 02:18 ET | 1200 | 27.81 |
| 02:20 ET | 843 | 27.765 |
| 02:21 ET | 500 | 27.78 |
| 02:23 ET | 1200 | 27.74 |
| 02:25 ET | 600 | 27.76 |
| 02:27 ET | 436 | 27.71 |
| 02:30 ET | 300 | 27.765 |
| 02:32 ET | 1697 | 27.815 |
| 02:34 ET | 100 | 27.8125 |
| 02:36 ET | 600 | 27.765 |
| 02:38 ET | 2129 | 27.67 |
| 02:39 ET | 300 | 27.58 |
| 02:41 ET | 400 | 27.55 |
| 02:43 ET | 300 | 27.575 |
| 02:45 ET | 400 | 27.58 |
| 02:48 ET | 100 | 27.575 |
| 02:50 ET | 700 | 27.575 |
| 02:52 ET | 100 | 27.54 |
| 02:54 ET | 200 | 27.54 |
| 02:56 ET | 900 | 27.54 |
| 02:57 ET | 300 | 27.53 |
| 02:59 ET | 100 | 27.5 |
| 03:01 ET | 2700 | 27.595 |
Today
Yesterday
Nov 22, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 11:01AM ET on Friday Nov 22, 2024 by Dow Jones
11:01AM ET on Friday Nov 22, 2024 by Dow JonesBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation, from 10:01AM ET on Friday Nov 22, 2024 by Dow Jones
10:01AM ET on Friday Nov 22, 2024 by Dow Jones
Nov 21, 2024
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation, from 10:01AM ET on Thursday Nov 21, 2024 by Dow Jones
10:01AM ET on Thursday Nov 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Spyre Therapeutics Inc | 1.6B | -3.7x | --- |
Viridian Therapeutics Inc | 1.6B | -4.9x | --- |
Neumora Therapeutics Inc | 1.6B | -5.5x | --- |
Celldex Therapeutics Inc | 1.8B | -10.9x | --- |
Praxis Precision Medicines Inc | 1.4B | -7.2x | --- |
Day One Biopharmaceuticals Inc | 1.4B | -13.2x | --- |
Company Information
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).
Contact Information
- Headquarters
- 221 Crescent Street, Suite 105WALTHAM, MA, United States 02453
- Phone
- 617-651-5940
- Fax
- 302-636-5454
Executives
- Chief Operating Officer
- Cameron Turtle
- Chief Financial Officer
- Scott Burrows
- Chief Medical Officer
- Sheldon Sloan
- Chief Legal Officer, Corporate Secretary
- Heidy King-Jones
- Director
- Mark Mckenna
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.85 |
EPS | $-7.44 |
Book Value | $7.45 |
P/E Ratio | -3.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
